Healthcare Private Placement and M&A Transactions Review Week Ending July 17 2022

Artio Medical: The company raised $28 million of Series A venture funding from undisclosed investors on July 16, 2022. The company is a developer of medical devices designed to develop innovative products for the treatment of peripheral vascular, neurovascular, and structural heart diseases.

Accelus: The company raised $12 million of Series D venture funding in a deal led by Concord Health Partners on July 12, 2022, putting the company’s pre-money valuation at $330 million. The company is a developer of medical implants designed to focus on expandable interbody technology for spine surgery.

Notable Labs: The company raised $10 million of venture funding from undisclosed investors on July 15, 2022. The company is an operator of a therapeutics business intended to develop predictive precision medicines.

InhaTarget Therapeutics: The company raised EUR 3.3 million of venture funding from Laboratoires S.M.B., Galephar Pharmaceutical Research, SambrInvest and other undisclosed investors on July 13, 2022, putting the company’s pre-money valuation at EUR 8.6 million. The company is a developer of an inhalable powdered medicine intended to improve lung cancer treatment.

Levee Medical: The company raised $3.2 million of Series A venture funding from undisclosed investors on July 13, 2022. The company is a developer of urological devices designed to improve recovery outcomes post-prostatectomy.

---

ProKidney / Social Capital Suvretta Holdings III: The company acquired Social Capital Suvretta Holdings III through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol PROK on July 12, 2022. ProKidney Corp is a clinical-stage biotechnology company with a proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient’s own cells isolated from the patient intended for treatment.

Entasis Therapeutics / Innoviva: The company was acquired by Innoviva for $113 million on July 11, 2022. Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.